<DOC>
	<DOC>NCT00347217</DOC>
	<brief_summary>Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin na√Øve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.</brief_summary>
	<brief_title>Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>The patient has a high risk of a cardiovascular event as defined by the European guidelines. The patient is statinnaive (i.e. has not used a statin &gt; 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin. An LDLC level is known for the statinnaive patient or for the statin used during visit 1. It has been decided to start the patient on CRESTOR 5 mg. The patient is prepared to give permission to the coded data being made available to AstraZeneca The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment. Contraindications for treatment with CRESTOR (see 1 B1 text). Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>LDL-C goal</keyword>
	<keyword>observational study</keyword>
	<keyword>primary prevention</keyword>
	<keyword>secondary prevention</keyword>
</DOC>